UNSPSC 51372105: Ethylmorphine

This classification denotes an opioid receptor agonist with the molecular structure C19H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, RWO67D87EU chemically known as (5.alpha.,6.alpha.)-7,8-didehydro-4,5-epoxy-3-ethoxy-17-methylmorphinan-6-ol but generally known as ethylmorphine, which bears US NIH Compound Identifier 5359271. European Medicines Agency schedules Ethylmorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13765MIG.

As of Q4 2014, ETHYLMORPHINE remains the US FDA Preferred Term for this commodity. Ethylmorphine bears US NLM identifiers UMLS ID C0015109 and NCI Concept Code C83704. SMILES: O1C2C34C(C(N(CC3)C)CC3C4C1C(OCC)CC3)C=CC2O.

UNSPSC 51372105 Ethylmorphine is a Commodity code that captures pharmaceutical procurement for specific active pharmaceutical ingredients and finished-form medications, but recent state and local opportunities under this code show activity focused instead on broader pharmaceutical and medical supply acquisition—including naloxone, generic pharmaceuticals, and over-the-counter products supplied through authorized wholesalers. State and local governments buying under this code are purchasing medications and health-related products for community health programs, emergency response initiatives, and multi-state cooperative purchasing agreements. Issuing bodies include county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances. The scope reflects both direct procurement of finished pharmaceutical products (such as naloxone for overdose response) and participation in cooperative purchasing frameworks that aggregate demand across multiple jurisdictions to negotiate volume pricing and standardized distribution through authorized pharmaceutical wholesalers.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with responses due July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative focused on direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. Vendors responding to MMCAP must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two authorized wholesalers, and carry commercial general liability of $5,000,000 per occurrence.